EPISODE · Nov 14, 2022 · 13 MIN
S7 Ep47: FDA Approval Insights: Teclistamab in Relapsed/Refractory Multiple Myeloma
from OncLive® On Air · host OncLive® On Air
Dr Garfall discusses the FDA approval of teclistamab in relapsed/refractory multiple myeloma, key efficacy and safety data from the MajesTEC-1 trial, and the drug’s unique mechanism of action compared with other anti-myeloma agents.
Embed this episode
NOW PLAYING
S7 Ep47: FDA Approval Insights: Teclistamab in Relapsed/Refractory Multiple Myeloma
0:00
13:35
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of OncLive® On Air?
This episode is 13 minutes long.
When was this OncLive® On Air episode published?
This episode was published on November 14, 2022.
Can I download this OncLive® On Air episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!